Aethlon Medical said it has begun a research study to validate the ability of the Aethlon Hemopurifier to capture viruses that are associated with increased mortality in immune-suppressed sepsis patients.
The study is designed to validate the in vitro capture of Cytomegalovirus, Epstein-Barr virus and Herpes Simplex Viruses. Upon successful completion, Aethlon will seek to demonstrate that the Hemopurifier can simultaneously capture all three viruses.
Aethlon recently completed a sepsis-related Department of Defense contract with the Defense Advanced Research Projects Agency (DARPA). Under the DARPA program, the company achieved 29 of 29 milestone opportunities, which generated approximately $5.9 million in revenues over the life of the contract.